NKTR
Nektar Therapeutics
43.60$
-7.3%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -1.1% | -9.4% | +8.5% | +2.7% | +20.9% | -64.1% | +6.8% | +5.5% | +85.0% | -50.2% | -6.7% | – | |
| – | -41.4% | +17.2% | +14.1% | -54.5% | +79.9% | -94.7% | -49.8% | -8.4% | -100.0% | – | – | – | |
| – | +41.7% | -21.1% | +4.9% | +43.2% | +7.7% | -50.7% | +6.8% | +3.7% | +88.1% | -50.9% | -5.4% | – | |
| – | +24.4% | -8.5% | +8.5% | +17.9% | -17.9% | +6.0% | -1.9% | -8.8% | +9.0% | +20.1% | +9.7% | – | |
| – | -18.1% | +16.3% | +1.8% | -7.6% | -9.6% | +42.1% | -29.9% | -7.0% | -28.3% | +18.1% | -5.0% | – | |
| – | -11.4% | -3.2% | +30.9% | -14.9% | -87.3% | +702.8% | -13.8% | -9.0% | -5.2% | +19.7% | +7.2% | – | |
| – | – | – | – | – | – | -410.4% | – | – | – | – | – | – | |
| – | +16.2% | -19.5% | +15.9% | -6.1% | +68.7% | -51.0% | +8.4% | +12.1% | +61.6% | -18.7% | -9.3% | – | |
| – | – | – | – | – | – | -825.9% | – | – | – | – | – | – | |
| – | – | – | – | -80.4% | -2,977.8% | – | -461.5% | – | – | +106.5% | -96.9% | – | |
| – | – | – | – | – | – | -800.8% | – | – | – | – | – | – | |
| – | – | – | – | – | – | -334.3% | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.